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■ Abstract
Background: Desensitization has been used for some decades to treat patients with the allergenic drug when an alternative drug with 
similar effi cacy and safety is not available. We present the results from a series of oncology patients desensitized at our hospital during 
the last 2 years.
Objective: To assess the effi cacy of a new desensitization protocol in patients allergic to chemotherapy drugs.
Methods: We performed an observational retrospective study of 11 women (6 breast cancer and 5 ovarian cancer) who underwent our 
desensitization protocol. Four patients had immediate reactions to carboplatin, 3 to docetaxel, 3 to paclitaxel, and 1 to both docetaxel 
and paclitaxel. Premedication was administered in all cases. A 5-step protocol based on 5 different dilutions of the drugs was used. 
Results: We performed 39 desensitization procedures: 14 to carboplatin, 3 to oxaliplatin, 16 to docetaxel, and 6 to paclitaxel. Eight patients 
tolerated the full dose in 36 procedures. One patient suffered an anaphylactic reaction to carboplatin that reverted with treatment. One 
patient had dyspnea after a paclitaxel cycle. One patient experienced dyspnea due to chronic pulmonary thromboembolism related to 
her disease.
Conclusion: Desensitization is a useful procedure in patients who are allergic to their chemotherapy agents.
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■ Resumen
Antecedentes: La desensibilización con medicamentos es un procedimiento utilizado desde hace varias décadas que permite tratar a pacientes 
con el fármaco al que son alérgicos, cuando no existe un fármaco alternativo con similar perfi l de efi cacia y seguridad. Presentamos los 
resultados de los pacientes oncológicos desensibilizados en nuestro Hospital en los últimos dos años.
Objetivos: Comprobar la efi cacia de un protocolo nuevo de desensibilización en pacientes alérgicos a citostáticos.
Métodos: Se trata de un estudio observacional retrospectivo. Once mujeres adultas (6 con cáncer de mama y 5 con cáncer de ovario) fueron 
tratadas mediante nuestro protocolo de desensibilización. Cuatro pacientes habían sufrido reacciones inmediatas previas con carboplatino, 
3 con docetaxel, 3 con paclitaxel y 1 con ambos taxanos. Se administró premedicación en todos los casos. Se utilizó un protocolo en cinco 
pasos, utilizando 5 diluciones del fármaco a administrar.
Resultados: Se realizaron un total de 39 desensibilizaciones: 14 a carboplatino, 3 a oxaliplatino, 16 a docetaxel y 6 a paclitaxel. Ocho 
pacientes toleraron la dosis completa del fármaco en 36 desensibilizaciones. Una paciente sufrió una reacción anafi láctica a carboplatino que 
respondió al tratamiento. Una paciente padeció disnea tras un ciclo de paclitaxel. Una paciente sufrió disnea debido a un tromboembolismo 
venoso relacionado con su enfermedad.
Conclusión: La desensibilización es un procedimiento útil para agentes quimioterápicos en pacientes alérgicos.
Palabras clave: Carboplatino. Quimioterapia. Desensibilización. Reacciones de hipersensibilidad. Paclitaxel.
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Introduction
Hypersensitivity reactions to taxanes and platins are not rare 
events. In the case of platins, these reactions are thought to be 
immunoglobulin (Ig) E–mediated, whereas taxanes elicit the 
release of mast cells and basophils. Hypersensitivity reactions to 
these drugs represent a challenge, because in some instances no 
alternative treatment is available. Consequently, the only option 
is to desensitize the patient to the chemotherapy agent. 
Since the fi rst desensitization protocol with drugs was 
described in a penicillin-allergic pregnant woman with syphilis, 
several empirical approaches have been developed [1]. They all 
involve suboptimal administration of the culprit drug followed 
by progressive dose increases. The mechanism through which 
tolerance is achieved is not known. Recent studies reported a 
role for certain molecules, such as the spleen tyrosine kinase 
gene [2] and the signal transducer and activator of transcription 6 
gene [3].
In recent years, a signifi cant number of desensitization 
procedures have been reported in patients receiving chemotherapy. 
Available data show that out of 413 desensitization procedures 
performed in 98 patients, 94% were well-tolerated or involved 
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Table 1. Patient Characteristics
  Patient Age, y Illness Symptoms Allergenic Drug Number Cycles  
 1 57 Ovarian cancer Dyspnea, chest Carboplatin 5
    pain, sickness 
 2 30 Ovarian cancer Dyspnea  Docetaxel 1
    desaturation Paclitaxel
 3 74 Ovarian cancer Palmar pruritus, Carboplatin 9
    facial rash, nausea 
 4 35 Breast cancer Genital pruritus, Paclitaxel 2
    shivering, dyspnea
 5 42 Ovarian cancer Rash, pruritus, Carboplatin 12
    facial edema
 6 72 Breast cancer Dyspnea, chest Docetaxel 1
    pain, sickness, 
    loss of conscience
 7 51 Breast cancer Facial edema, Docetaxel 1
    dysphagia, dyspnea
 8 59 Breast cancer Facial edema, Paclitaxel 5
    dysphagia, chest
    pain
 9 38 Breast cancer Dyspnea, cyanosis, Docetaxel 1
    facial rash,
    conjunctivitis 
 10 64 Ovarian cancer Palmoplantar Carboplatin 8
    pruritus, rash,
    abdominal pain,
    dyspnea, nausea
 11 58 Breast cancer Dyspnea, laryngeal Paclitaxel 2
    edema, rash,
    desaturation
only mild reactions, with all patients being able to tolerate the 
full dose [4]. The total duration of the protocol used in these 
studies was 5 hours and 49 minutes.
The departments of Allergy, Oncology, and Pharmacy at 
our institution (Clinica Universidad de Navarra, Pamplona, 
Spain) collaborated to develop a desensitization protocol for 
taxanes and platins. Our aim was to administer the full dose in 
half the time of previously reported protocols. We report our 
results 3 years after implementing the protocol.
Methods
We performed an observational retrospective analysis of 
all patients who underwent desensitization protocols in 2006 
and 2007.
Patients
Eleven women aged 30 to 74 years were included in the 
study. All the patients were receiving chemotherapy in our 
Oncology Department. Six patients had breast cancer and 5 
had ovarian cancer. Four patients had reacted to carboplatin, 
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3 to docetaxel, 3 to paclitaxel, and 1 to both docetaxel and 
paclitaxel. The individual features of the disease and reactions 
recorded during chemotherapy are summarized in Table 1. 
Depending upon the culprit drug, the reaction appeared at 
different stages of treatment. Carboplatin was associated with 
reactions between the fi fth and twelfth chemotherapy cycle. 
Paclitaxel provoked a reaction during the fi rst cycle in 1 patient 
and during the second cycle in 3 patients. Finally, in the case of 
docetaxel, all reactions were present during the fi rst cycle.
Patients younger than 18 years were excluded. Before 
the protocol was administered, all patients gave their 
written informed consent after a complete oral and written 
explanation. 
To be eligible to undergo the protocol, the patients must 
have suffered an immediate reaction within less than 1 hour 
after initiation of chemotherapy. Patients with a delayed drug 
reaction were excluded. We did not desensitize patients to 
whom an alternative drug with a similar effi cacy profi le could 
be administered.
We considered an allergic reaction to be a typical 
immediate hypersensitivity reaction involving cutaneous 
symptoms (urticaria with or without angioedema, fl ushing, 
itching), respiratory symptoms (shortness of breath, oxygen 
desaturation, cough, wheezing, chest tightness), cardiovascular 
symptoms (tachycardia, syncope, hypotension, hypertension), 
and gastrointestinal symptoms (nausea, vomiting, diarrhea). 
Patients who experienced atypical symptoms–shortness of 
breath, lumbar pain, or gastrointestinal symptoms, with no 
involvement of other systems–were excluded.
Diagnostic Procedures
We were unable to perform skin tests on all patients for 
logistic reasons (eg, timing and availability of chemotherapy 
agents). When they were performed, we used carboplatin 
(10 mg/mL for the prick test and 1 and 10 mg/mL for the 
intradermal test), oxaliplatin (5 mg/mL for the prick test and 
0.5 and 5 mg/mL for the intradermal test), paclitaxel (0.6 mg/mL 
for the prick test and 0.06 mg/mL for the intradermal skin test), 
and docetaxel (0.4 mg/mL for the prick test and 0.04 mg/mL 
for the intradermal skin test). 
We also performed the basophil activation test as described 
elsewhere [5]. Carboplatin and oxaliplatin were tested at a fi nal 
concentration of 0.125 mg/mL and 0.03 mg/mL. Paclitaxel 
was tested at a final concentration of 0.0075 mg/mL and 
0.0018 mg/mL, and docetaxel at a fi nal concentration of 0.005 mg/mL 
and 0.00125 mg/mL.
Desensitization Protocol
The local ethics committee approved the protocol. Each 
patient underwent the fi rst desensitization in the intensive 
care unit. Subsequent desensitizations were performed in an 
observation unit for close monitoring with 1 nurse for every 
3 patients. 
Premedication was administered in all cases and 
consisted of 60 mg of oral prednisone at 13 hours, 7 hours, 
and 1 hour before the procedure plus 5 mg of intravenous 
dexchlorpheniramine 1 hour before the procedure.
Drug Administration Procedure
Once the individual dose was calculated, we followed a 
rush protocol consisting of 5 drug delivery stages. An example 
of the protocol used in desensitization with carboplatin is 
summarized in Table 2. For the fi rst 4 dilutions, the rate of 
intravenous administration was 150-200 mL/h; the last dilution 
was delivered at 280mL/h for carboplatin, 167 mL/h for 
oxaliplatin, 80 mL/h for paclitaxel, and 125 mL/h for docetaxel. 
Depending on the total dose and the drug, the procedure lasted 
from 2 to 5 hours.
Management of Adverse Reactions
If a mild reaction occurred, we suspended the infusion and 
administered 0.5 mg/kg of methylprednisolone. If the reaction 
involved respiratory symptoms, we also administered 5 mg 
of salbutamol nebulized over 5 minutes. Once the symptoms 
resolved, we continued with the procedure.
In cases of severe or moderate reaction, or when a mild 
reaction and the same symptoms appeared upon reinfusion, we 
started the infusion with the previous tolerated dose and rate. 
Administration was only interrupted in cases of anaphylactic 
shock, for which epinephrine was injected.
Results
Skin tests were performed in 5 patients, 3 with taxanes and 
2 with platins. We observed 1 isolated positive skin reaction 
with docetaxel.
We also performed the basophil activation test in 4 patients, 2 
with taxanes and 2 with platins. All the results were negative.
We performed 39 desensitization protocols: 14 with 
carboplatin, 3 with oxaliplatin, 16 with docetaxel, and 6 with 
paclitaxel (Table 3).
Table 2. Desensitization Protocol for Carboplatin
   Volume, mL Infusion Time,  Time Dose Cumulative
   min Accumulated Administered, mg Dose, mg  
 
Solution A, 1/10000 50 15 15 0.03 0.03
Solution B, 1/1000 50 15 30 0.30 0.33
Solution C, 1/100 50 15 45 3.00 3.33
Solution D, 1/10 50 15 60 30.00 33.33
Solution E, 1/1 280 60 120 266.67 300.00
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Table 3. Desensitization Protocols
  Patient Drug Number of Cycles  Tolerance Cutaneous BAT
  Sensitized Performed  Tests   
 
 1 Carboplatin 2 Yes – –
  Oxaliplatin 3 
 2 Paclitaxel 1 Dyspnea ND ND
  Docetaxel 2 Yes 
 3 Carboplatin 2 Yes ND ND
 4 Docetaxel 2 Yes – ND
 5 Carboplatin 9 Yes – –
 6 Docetaxel 4 Yes (chronic PTE) ND ND
 7 Docetaxel 4 Yes – –
 8 Paclitaxel 3 Yes ND ND
 9 Docetaxel 4 Yes Docetaxel, + –
     Paclitaxel, –
 10 Carboplatin 1 Anaphylaxis ND ND
 11 Paclitaxel 2 Yes ND ND
 
Abbreviations: BAT, basophil activation test; ND, not done; PTE, pulmonary thromboembolism.
We were able to administer the full dose to all but 1 patient. 
Thirty minutes after the beginning of the last stage (approximately 
352 mg of carboplatin) in the fi rst desensitization, the patient 
developed grade II anaphylaxis with no cardiovascular 
symptoms that resolved 30 minutes after administration of 
methylprednisolone and dexchlorpheniramine.
Overall, 3 patients suffered an adverse reaction. One 
patient with hypersensitivity to docetaxel plus paclitaxel 
suffered from dyspnea with the last dose of paclitaxel; 
consequently, docetaxel was administered during the 
following 2 desensitizations without incident. After 4 
desensitizations, 1 patient developed late shortness of breath 
due to chronic pulmonary thromboembolism associated 
with her disease. One patient suffered an anaphylactic 
reaction.
The remaining 8 patients tolerated the desensitization 
protocol without incident.
As for the efficacy of chemotherapy, tumor markers 
decreased after desensitization in 4 patients and increased in 
5 (indicating disease progression). No data were available on 
tumor markers for 2 patients. 
Discussion
Rapid desensitization protocols make it possible to 
administer treatment to patients who experience hypersensitivity 
reactions to chemotherapy agents such as taxanes [6], platins 
[7,8], and monoclonal antibodies [9]. We were able to achieve 
desensitization in all but 1 patient, even after shortening the 
protocol by more than 2 hours.
The patient who discontinued the protocol did so on the 
advice of her oncologist, who decided to try another drug for 
reasons of safety. 
Our data show that desensitization protocols are not risk-
free, and we do not have the means available to assess this 
risk. The case of cancer patients is particularly challenging, 
as chemotherapy is often the only way their disease can be 
controlled; consequently, more severe measures may be 
necessary to ensure drug delivery. 
The adverse reactions we observed are consistent with the 
fi ndings of other authors. Hypersensitivity reactions with platins 
usually appear when the patient has received more than 4-6 
cycles, whereas taxanes produce reactions during the fi rst or 
second chemotherapy cycle [4]. Consequently, the reaction is 
thought to be IgE-mediated in the case of platins. In fact, several 
authors recommend a positive skin test result as a predictor of 
future platin reactions [10]. Despite reports of a high incidence 
of positive skin test results with carboplatin [11], the 2 patients 
who suffered reactions to carboplatin in our study had negative 
results (in one of them the study was performed 1 year after she 
suffered the reaction). Studies must be performed to assess the 
specifi city and sensitivity of skin tests to platins. 
We investigated an in vitro marker of cell activation. 
However, we did not find any CD63 expression upon 
incubation of basophils with the chemotherapy agent involved. 
This might be because these reactions are mediated purely by 
mast cells or by the patient’s immunodepressed state. 
Our protocol differs from others applied in larger series 
[4], the main advantages being that our protocol is shorter and 
has fewer nursing care requirements. It also has fewer steps 
and, consequently, fewer administration errors. We used 5 
different drug dilutions and the procedure was completed in 
2 hours when well tolerated. Lee et al [7] used 3 dilutions 
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administered in twelve 15-minute steps, with a total duration 
of 5 hours and 49 minutes [7]. 
It is extremely useful to have different protocols in order 
to be able to choose approaches depending upon individual 
patient requirements. For instance, we think that the patient 
who developed an anaphylactic reaction could have tolerated 
the protocol of Lee et al [7]; however, as we mentioned 
above, it was impossible to assess this hypothesis, because 
her oncologist opted to change the treatment.
Nevertheless, protocols do not differ widely, since most 
of the drug is administered in the last step in all methods. 
Similarly, Lee et al [7] delivered 92% of the total dose in the 
last step within 3 hours. In our protocol, we administered 89% 
of the total drug dose in the last step in 1 hour. Thus, managing 
the pace of administration in this last step seems to play a key 
role in preventing adverse reactions. It would be interesting to 
compare the number of reactions between different approaches, 
since most occur during administration of the last doses [4]. 
The usefulness of premedication should also be borne 
in mind. This is a controversial issue. Some authors support 
avoiding it altogether [8], as early anaphylactic symptoms 
would be promptly recognized and treated. Other authors 
oppose this approach and recommend using premedication 
[7,12], as it prevents mild symptoms that could interfere with 
the procedure and increase patient anxiety. Moreover, the fi rst 
desensitization should be applied in the intensive care unit, not 
only for safety reasons, but also to reassure patients about the 
procedure. In our experience, diminishing patient stress makes 
subsequent desensitization easier.
We should bear in mind that the patient is constantly 
monitored. We think that while premedication does not 
completely protect against a severe allergic reaction, it is 
useful. Failed attempts to administer a drug that caused a 
hypersensitivity reaction using only premedication have been 
published [13]. Zorzou et al [14] used premedication and slow 
delivery; however, 77% of patients had a mild reaction, and the 
remaining patients could not achieve the total dose [14].
In conclusion, desensitization with chemotherapy agents 
could resolve an important problem for patients with cancer. 
However, this procedure involves a certain degree of risk. 
Our results show that it can be performed much more quickly 
than reported by other authors. Further studies are needed to 
compare outcomes from different protocols in order to be able 
to defi ne indications for different approaches. 
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